Rolziracetam
From Wikipedia, the free encyclopedia
Other names2,6,7,8-tetrahydro-1H-pyrrolizine-3,5-dione, CI 911 & Lukes-Šorm dilactam.
ATC code
- none
Legal status
- AU: S4 (Prescription only)
- US: Unscheduled
| Clinical data | |
|---|---|
| Other names | 2,6,7,8-tetrahydro-1H-pyrrolizine-3,5-dione, CI 911 & Lukes-Šorm dilactam. |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C7H9N2O2 |
| Molar mass | 153.161 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Rolziracetam is a nootropic drug of the racetam family.
Rolziracetam was found to improve performance on a delayed-response task in aged rhesus monkeys. It has a wide margin of safety in animals and has been evaluated for use in cognitively impaired human subjects.[1]